These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 27348021)
1. A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02. Tan CW; Tan-Koi WC; Ng J; Chan CM; Hwang WY Pharmacogenomics; 2016 Jul; 17(11):1235-1243. PubMed ID: 27348021 [TBL] [Abstract][Full Text] [Related]
3. Eprex-associated pure red cell aplasia and leachates. Schellekens H; Jiskoot W Nat Biotechnol; 2006 Jun; 24(6):613-4. PubMed ID: 16763579 [No Abstract] [Full Text] [Related]
4. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Stravitz RT; Chung H; Sterling RK; Luketic VA; Sanyal AJ; Price AS; Purrington A; Shiffman ML Am J Gastroenterol; 2005 Jun; 100(6):1415-9. PubMed ID: 15929778 [TBL] [Abstract][Full Text] [Related]
5. [Pure red cell aplasia developed during treatment with erythropoietin. Complete remission during immunosuppressive therapy]. Høi-Hansen T; Lauritzen AM; Hansen PB Ugeskr Laeger; 2003 May; 165(19):2001-2. PubMed ID: 12795077 [TBL] [Abstract][Full Text] [Related]
6. Epoetin alfa (Eprex): reports of pure red blood cell aplasia. Wooltorton E CMAJ; 2002 Feb; 166(4):480. PubMed ID: 11873930 [No Abstract] [Full Text] [Related]
7. Update on reintroduction of epoetin in a patient with pure red call aplasia. Campbell N; Krishnakumar S; Matijevic A; Almond M Nephrol Dial Transplant; 2008 Oct; 23(10):3365. PubMed ID: 18567693 [No Abstract] [Full Text] [Related]
8. Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework. Jacob S; Nichols J; Macdougall IC; Qureshi Z; Chen B; Yang YT; Norris LB; Bennett CL Am J Ther; 2018; 25(6):e670-e674. PubMed ID: 30169374 [TBL] [Abstract][Full Text] [Related]
9. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309. Praditpornsilpa K; Kupatawintu P; Mongkonsritagoon W; Supasyndh O; Jootar S; Intarakumthornchai T; Pongskul C; Prasithsirikul W; Achavanuntakul B; Ruangkarnchanasetr P; Laohavinij S; Eiam-Ong S Nephrol Dial Transplant; 2009 May; 24(5):1545-9. PubMed ID: 18689790 [TBL] [Abstract][Full Text] [Related]
10. Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? Macdougall IC; Roche A; Rossert J; Casadevall N; Francois P; Kemeny DM Nephrol Dial Transplant; 2004 Nov; 19(11):2901-5. PubMed ID: 15496566 [No Abstract] [Full Text] [Related]
11. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Bennett CL; Cournoyer D; Carson KR; Rossert J; Luminari S; Evens AM; Locatelli F; Belknap SM; McKoy JM; Lyons EA; Kim B; Sharma R; Costello S; Toffelmire EB; Wells GA; Messner HA; Yarnold PR; Trifilio SM; Raisch DW; Kuzel TM; Nissenson A; Lim LC; Tallman MS; Casadevall N Blood; 2005 Nov; 106(10):3343-7. PubMed ID: 16099877 [TBL] [Abstract][Full Text] [Related]
14. [Pure red blood cell aplasia associated with neutralizing antibodies against erythropoietin induced by epoetin alfa:a new form of acquired erythroblastopenia in auremic patients]. Cases A; Esforzado N; Mas M; Ricart MJ; Cruzado JM Nefrologia; 2003; 23(3):266-70. PubMed ID: 12891943 [TBL] [Abstract][Full Text] [Related]
15. [A deal with the Devil and Beelzebub]. Heinzl S Med Monatsschr Pharm; 2003 May; 26(5):145. PubMed ID: 12784499 [No Abstract] [Full Text] [Related]
16. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Mandreoli M; Finelli C; Lopez A; Ascani S; Vianelli N; Baccarani M; Santoro A Am J Kidney Dis; 2004 Oct; 44(4):757-61. PubMed ID: 15384028 [TBL] [Abstract][Full Text] [Related]
17. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Macdougall IC; Casadevall N; Locatelli F; Combe C; London GM; Di Paolo S; Kribben A; Fliser D; Messner H; McNeil J; Stevens P; Santoro A; De Francisco AL; Percheson P; Potamianou A; Foucher A; Fife D; Mérit V; Vercammen E; Nephrol Dial Transplant; 2015 Mar; 30(3):451-60. PubMed ID: 25239637 [TBL] [Abstract][Full Text] [Related]
18. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. Casadevall N; Nataf J; Viron B; Kolta A; Kiladjian JJ; Martin-Dupont P; Michaud P; Papo T; Ugo V; Teyssandier I; Varet B; Mayeux P N Engl J Med; 2002 Feb; 346(7):469-75. PubMed ID: 11844847 [TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of Antibody-mediated Pure Red Cell Aplasia Induced by Continuous Erythropoietin Receptor Activator with Prednisolone. Okahashi N; Kubo M; Hoshino E; Uchihara M; Amano I; Tanaka H Intern Med; 2022 Jul; 61(14):2209-2213. PubMed ID: 34980800 [TBL] [Abstract][Full Text] [Related]
20. Epoetin-induced pure red cell aplasia: diagnosis and treatment. Macdougall IC Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):585-8. PubMed ID: 18089975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]